Shingrix ko’s Zostavax

Discussion in 'GlaxoSmithKline' started by anonymous, Apr 10, 2018 at 8:30 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Wow, Merck is losing ground much faster than expected. Shingrix is destroying Merck’s inferior product. Time to load up on GSK stock and dump Merck.
     

  2. anonymous

    anonymous Guest

    Relax Warren Buffet. Lots of patients experiencing bad side effects with Shingrix.
     
  3. anonymous

    anonymous Guest


    Are you a lawyer or Merck rep?
     
  4. anonymous

    anonymous Guest

    The only side effect is the sales force of zostavax being laid off.
     
  5. anonymous

    anonymous Guest

    That was pretty funny!
     
  6. anonymous

    anonymous Guest

    There is some truth to the last comment. Vaccines has been able to hide behind Gen Pharma for quite awhile. There are high hopes for Shingrix. With those hopes come expectations and pressure. So, the pressure is on Vaccines! Show us what you can do. If you underperform your division will be cut by half. These are not my sentiments, rather what has essentially come from Emma at the last meeting in Dallas. Call averages are under scrutiny. We here in Pharma, the division that is responsible for 70% of sales, are keeping you to the fire. I for one love the fact that you actually have to perform...finally!
     
  7. anonymous

    anonymous Guest

    GSK should check themselves. It's more like the ACIP KO's ZOSTAVAX. GSK is very lucky they got the preferred reco from ACIP. Instead of the share of the market the focus will be on how well they do in growing the market. The pressure is indeed on now............
     
  8. anonymous

    anonymous Guest


    Call averages? Lol!! Sounds like a brainwashed pharma rep to me. Make sure you don’t enter calls on those D targets and definitely don’t sample them. Gotta make he metrics look good, because that’s what drives sales is mertics lol!!!! Don’t lecture another division on call averages and sales numbers, you sound rather ingorant around what is actually involved in the vaccine process. It’s not as simple as giving a 20 second commercial and handing your “pay no more than $10 card” to everyone. We have waaaaay too many reps in pharma and you know it. Vaccine division is expanding, growing, and is a lean sales force with very large geographies. Yes ACIP was a gift and we will turn that gift into a mega blockbuster!
     
  9. anonymous

    anonymous Guest

    I would argue that this is a time when direct to consumer advertising will be crucial. Most if not all folks over 50 have had chicken pox. The discussions should be with not only physicians but with the healthcare providers that are in the CVS and Walgreens clinics. Nobody wants to take time from work to have a vaccination. But with these clinics you can drop in and get your Shingrix shot. This has the potential to be way bigger than anyone has forecasted if GSK gets their act together.
     
  10. anonymous

    anonymous Guest

    Are you the marketing director ?
     
  11. anonymous

    anonymous Guest

    We didn't even sell that much of it yet, any supply issues this early are unacceptable. Wow. ACIP must be pissed.
     
  12. anonymous

    anonymous Guest

    An old ploy of GSK.......to get us to try harder before supply runs out......it's as simple as that !
     
  13. anonymous

    anonymous Guest


    You are joking right?
     
  14. anonymous

    anonymous Guest

    No, not kidding. We are a few months into this launch therefore we have not sold millions upon millions of doses and we are having conversations about supply issues. You don't think that is a problem? ACIP would have never given us the preferred recommendation if they knew a few short months into launch we would be dealing with backorders.
     
  15. anonymous

    anonymous Guest